In this study, participants are assigned to one of the treatment groups by chance. One group receives tirabrutinib alone, and the other group receives rituximab plus temozolomide. Treatment is given over a period of time with regular study visits, and health is checked throughout the study to see how the disease responds and how long the disease stays under control. The study also looks at overall survival, which means how long people live after joining the study, and at changes in steroid medicine use.

This is a Phase 3 study, which means the treatment is being compared in a larger group of people to help show how well it works and how safe it is. It is a randomized study, so the treatment group is chosen by chance, and it is open-label, which means both the study team and the participants know which treatment is being given.

The purpose of this study is to find out if lisocabtagene maraleucel can prevent the cancer from getting worse within one year after the treatment is given to patients who have not been able to receive a stem cell transplant. The study will also look at how long it takes for the cancer to get worse, how long patients live after joining the study, how many patients show no signs of cancer after treatment, and how long any improvements last. Additionally, the study will examine how the treatment affects patients’ daily lives and what side effects or health problems patients may experience during the study.

During the study, patients will first receive standard treatments to reduce their cancer as much as possible. Before receiving lisocabtagene maraleucel, patients will be given medications to prepare their body for the modified immune cells. The treatment involves collecting the patient’s own immune cells, modifying them in a laboratory, and then giving them back to the patient through an injection into a vein. Patients will be closely watched for any health problems and to see how well the treatment works. The study will continue to follow patients for several years to understand the long-term effects of the treatment.

The purpose of the study is to assess how effective Epcoritamab is when used alongside Lenalidomide and Rituximab in treating this specific type of lymphoma. Participants in the study will receive these medications over a series of treatment cycles. The study will monitor the response of the cancer to the treatment during the initial phase, which consists of eight cycles. The goal is to determine the best response rate, which includes complete or partial reduction of the cancer, as recommended by international guidelines for this type of lymphoma.

Throughout the study, participants will undergo regular assessments, including imaging tests like MRI (Magnetic Resonance Imaging), to evaluate the progress of the treatment. The study aims to provide valuable information on the effectiveness of this treatment combination, which could potentially lead to improved outcomes for patients with this challenging form of lymphoma.

The treatment involves several medications that are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The medications being studied include Etoposide Phosphate, Carboplatin, Methotrexate, Rituximab, and Cyclophosphamide. These drugs are commonly used in cancer treatment and work in different ways to stop the growth of cancer cells. Some patients in the study may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

The study will follow patients over a period of time to see how many are still alive at 2, 5, and 10 years after starting treatment. It will also look at how well the cancer responds to the treatment and any side effects, especially long-term effects on the nervous system. This information will help doctors understand how effective the treatment is and what side effects might occur, providing valuable insights for future treatment of PCNSL.

The trial will investigate a new medication called Golcadomide (also known by its code name CC-99282), which is taken orally in capsule form. This medication will be tested both on its own and in combination with other treatments for NHL, including Rituximab, Obinutuzumab, Tafasitamab, and Valemetostat Tosylate. Rituximab is a monoclonal antibody, which is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. The purpose of the study is to determine the safety and tolerability of Golcadomide alone and in combination with these other treatments, as well as to find the best dose to use in future studies.

Participants in the study will receive the medication and be monitored for any side effects or changes in their condition. The study will also look at how the body processes the medication and its preliminary effectiveness in treating the disease. The trial is designed to gather important information that could lead to new treatment options for people with relapsed or refractory NHL.

The purpose of this study is to determine if the new treatment strategy can improve the time patients remain free from events such as treatment failure, cancer progression, or death, compared to the standard approach. Participants in the study will receive the medications through an intravenous infusion, which means the drugs are delivered directly into the bloodstream. The study will compare the outcomes of the new treatment plan with the standard treatment to see which is more effective in helping patients achieve remission, which is a period when the cancer is not active.

Throughout the study, researchers will monitor various aspects of the participants’ health, including overall survival, progression-free survival, and quality of life. The trial is expected to continue until 2030, allowing researchers to gather comprehensive data on the effectiveness and safety of the new treatment approach. This study is an important step in finding better ways to treat PCNSL and improve the lives of those affected by this challenging condition.

The purpose of the study is to understand how [18F]fludarabine spreads in the brain and how much of it is absorbed by the cancer before any surgery, chemotherapy, or radiotherapy is done. Participants will undergo imaging tests to see how the drug interacts with the cancer and healthy brain tissue. The study will help researchers learn more about the behavior of this type of lymphoma and how it can be better diagnosed and treated in the future.

During the study, participants will receive the [18F]fludarabine infusion and undergo PET-MRI scans. These scans will help measure the amount of the drug in the tumor compared to healthy tissue. The study will also look at other factors like the size of the tumor and how it affects the brain. This research aims to provide valuable insights into the treatment and management of primary central nervous system lymphoma.

The purpose of the study is to evaluate the safety and tolerability of Berubicin when used in combination with other cancer-fighting drugs, known as cytostatic agents. The study aims to determine the best dose of Berubicin for future research. Participants in the trial will receive either Berubicin or a placebo, and their health will be monitored closely to assess how well the treatment works and how it affects their body. The study will also look at how long patients live without the disease getting worse and how many patients respond positively to the treatment.

Throughout the study, researchers will collect information on the participants’ health, including their response to the treatment and any side effects they experience. The trial will also involve regular check-ups and tests to monitor the participants’ progress. The study is expected to continue until early 2027, with the goal of improving treatment options for patients with CNS lymphomas.

Participants in the study will take the medications orally, meaning they will swallow them in the form of tablets. The study will begin with a phase where the dose of CA-4948 is gradually increased to find the safest and most effective dose. After this phase, the study will expand to include more patients to further assess the treatment’s safety and how well it works. Throughout the study, doctors will monitor participants closely for any side effects and changes in their health. The study aims to provide valuable information about the potential benefits and risks of using CA-4948 in combination with Ibrutinib for treating PCNSL.

This trial is expected to continue until 2028, allowing researchers to gather comprehensive data on the treatment’s long-term effects. Participants will undergo regular health check-ups, including tests like MRI scans, to track the progress of their condition and the impact of the treatment. The study is designed to ensure that all participants receive the best possible care while contributing to important research that could improve future treatment options for PCNSL.

The purpose of the study is to find a treatment plan that is both practical and effective for patients with PCNSL. Participants in the study will receive these medications over a period of time, and their response to the treatment will be monitored. The study will look at how well the cancer responds to the treatment after at least two cycles, which are periods during which the medication is given. The study will also assess the overall response after four cycles, as well as the time patients remain free from cancer progression and their overall survival.

Throughout the study, the safety of the treatment will be closely monitored by checking for any side effects or adverse events. The study will also evaluate the quality of life and cognitive function of the participants using specific questionnaires. The goal is to ensure that the treatment is not only effective but also safe and manageable for patients. This trial aims to provide valuable information that could lead to better treatment options for those affected by PCNSL.